SBC at a glance
SBC Medical Group Holdings Inc (SBC, SEC CIK 1930313) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as April 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), SBC Medical Group Holdings Inc (SBC) reported revenue of $173.6 million (down 15.5% from FY2024) and net income of $51.0 million. Diluted EPS was $0.50.
- As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding SBC Medical Group Holdings Inc (SBC) shares worth $9.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Aikawa Yoshiyuki on April 28, 2026 of 465,000 shares at $3.02 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $173.6M
- −15.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 18 funds
- $9.7M · +2 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New Nasdaq compliance risk: independent director departure triggered board and audit committee violations on July 8, 2026
- Most material update: delisting risk, Nasdaq cure period runs through July 9, 2027
- Regulatory risk: delisting could reduce liquidity and classify common stock as a penny stock
- Operational risk: failure to appoint independent directors could prevent restored Nasdaq compliance
- Financial risk: delisting could decrease ability to issue securities or obtain future financing
Management Discussion & Analysis
- Quarterly revenue $58.6M, up 35.13% YoY from $43.4M
- Operating margin 45.09% vs 36.63% YoY, net income margin 26.79% vs 29.58%
- Best line management services revenue $16.4M, up 73.28%; weakest franchising revenue $9.6M, down 3.60%
- Cash $198.4M vs $163.8M at December 31, 2025; operating cash flow $50.2M vs $(27.3)M
- Capital deployment: $8.9M borrowing repayments, $5.0M investment commitment, no share repurchases under $20.0M authorization
AI summary of the SBC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Cybersecurity incidents occurred in Japan on November 16, 2026
- Potential effects on business, financial condition and results remain undetermined
Item EX-99.1: Item EX-99.1
- Cyberattack exposed customer databases, affecting 1,624,000 basic records and additional reservation, inquiry, treatment-monitor, and review data
- Employee data compromised, including approximately 20,000 account records and sensitive employment information for 459 employees
Item 2.02: Results of Operations and Financial Condition
- Press release announces SBC Medical Group Holdings’ quarterly results for the period ended September 30, 2026
- Exhibit 99.1 contains the financial results and management commentary investors need for performance assessment
Item 7.01: Regulation FD Disclosure
- Investor presentation covers 3Q 2026 results for quarter ended September 30, 2026
- Presentation posted November 13, 2026 at SBC Medical Group’s investor-relations website
Item EX-99.1: Item EX-99.1
- 3Q26 revenue $59 million, up 35%, driven by higher management fees, service-fee revisions and Waqoo consolidation
- Operating income $26 million, up 66%, with 45% margin, indicating substantial operating leverage
Item EX-99.1: Item EX-99.1
- Q2 revenue $49M, up 13% YoY, signaling growth reacceleration after 2025 restructuring
- Net income attributable to SBC Medical $11M, up 335%, with margin expanding to 22% from 6%
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 announces SBC Medical Group Holdings’ results for the quarter ended June 30, 2026
- Quarterly financial figures and management commentary are contained in the attached earnings release
Item 7.01: Regulation FD Disclosure
- 2Q 2026 investor presentations posted August 13, 2026
- Materials cover business overview and results for quarter ended June 30, 2026
AI summaries of SBC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SBC
Don't miss the next SBC filing
- Alerts as it files. A push when SBC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SBC, by share count.
- Ask anything. An AI agent that reads every SBC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Aikawa Yoshiyuki | Sell | Apr 28, 2026 | 465,000 | $3.02 |
| Aikawa Yoshiyuki | Sell | Apr 21, 2026 | 3,100,000 | $3.02 |
| Aikawa Yoshiyuki | Sell | Mar 6, 2026 | 4,422,900 | $2.12 |
| Aikawa Yoshiyuki | J | Mar 6, 2026 | 44,229 | - |
| Aikawa Yoshiyuki | J | Mar 6, 2026 | 44,229 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $205.4M | $173.6M |
| Gross Profit | - | $156.1M | $127.3M |
| Operating Income | - | $70.3M | $67.5M |
| Net Income | - | $46.6M | $51.0M |
| Gross Margin | - | 76.0% | 73.3% |
| Op. Margin | - | 34.2% | 38.9% |
| Net Margin | - | 22.7% | 29.4% |
| Balance Sheet | |||
| Total Assets | - | $266.1M | $380.4M |
| Equity | -$6.0M | $195.1M | $248.3M |
| ROE | - | 23.9% | 20.5% |
| Per Share | |||
| EPS | $0.42 | $0.48 | $0.50 |
| Cash Flow | |||
| Operating CF | - | $20.6M | $24.7M |
| CapEx | - | $2.6M | $1.4M |
Source: XBRL data in SBC Medical Group Holdings Inc (SBC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SBC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 18 | $9.7M |
| Q2 2026 | 16 | $5.1M |
| Q1 2026 | 14 | $3.4M |
| Q4 2025 | 13 | $3.8M |
| Q3 2025 | 12 | $2.3M |
| Q2 2025 | 11 | $1.9M |
| Q1 2025 | 1 | $3,000 |
- BlackRock+150.1K (+16%)
- Vanguard Capital Management LLC+71.0K (+52%)
- AQR Capital Management+36.7K (+152%)
- State Street Corp+29.0K (+59%)
- Bank of America Corp+26.5K (+232%)
- Citadel Advisors LLC−84.0K (-58%)
- Wells Fargo & Co−12.4K (-77%)
- Citigroup−6.4K (-72%)
- Goldman Sachs Group+50.1K
- Millennium Management+13.4K
- Invesco Ltd+11.8K
- FMR LLC (Fidelity)−10.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 85 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SBC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 10-Q | Nov 13, 2026 | Sep 30, 2026 | Analysis | |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 8-K | May 20, 2026 | - | Analysis | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 29, 2026 | - | - | - |
| 4 | Apr 23, 2026 | - | - | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 10-K | Mar 27, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 27, 2026 | - | - | - |
| SC 13G | Mar 13, 2026 | - | - | |
| 4 | Mar 10, 2026 | - | - | - |
| 8-K | Jan 5, 2026 | - | - | |
| 8-K | Dec 31, 2025 | - | - | |
| 8-K | Dec 15, 2025 | - | - | |
| 10-Q | Nov 14, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 13, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 15, 2025 | Mar 31, 2025 | - | |
| 10-K | Mar 28, 2025 | Dec 31, 2024 | Analysis | |
| 10-Q | Nov 13, 2024 | Sep 30, 2024 | - | |
| SC 13D | Sep 23, 2024 | - | - |
Related Health Care companies
- AIRS · Airsculpt Technologies, Inc.Services-Offices & Clinics of Doctors of Medicine
- HIMS · Hims & Hers Health, Inc.Services-Offices & Clinics of Doctors of Medicine
- LFMD · LifeMD, Inc.Services-Offices & Clinics of Doctors of Medicine
- TOI · Oncology Institute, Inc.Services-Offices & Clinics of Doctors of Medicine
- TDOC · Teladoc Health, Inc.Services-Offices & Clinics of Doctors of Medicine
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
SBC SEC filings: frequently asked questions
Which institutions hold SBC stock?
As of September 30, 2026, the largest SBC Medical Group Holdings Inc (SBC) holders among the 13F filers tracked by SignalX were BlackRock ($5.3 million), Vanguard Capital Management LLC ($1.0 million), Northern Trust ($724,000), Vanguard Portfolio Management LLC ($650,000), State Street Corp ($386,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SBC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), SBC Medical Group Holdings Inc (SBC) reported revenue of $173.6 million (down 15.5% from FY2024) and net income of $51.0 million. Diluted EPS was $0.50. The figures come from the XBRL data in the 10-K.
What did SBC report in its latest 8-K?
SBC Medical Group Holdings Inc (SBC) filed an 8-K on November 19, 2026 reporting Item 8.01 (Other Events). Cybersecurity incidents occurred in Japan on November 16, 2026.
What are the latest SBC SEC filings?
SBC Medical Group Holdings Inc (SBC) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on April 29, 2026.
What is SBC's SEC CIK number?
SBC Medical Group Holdings Inc (SBC)'s SEC Central Index Key (CIK) is 1930313. EDGAR lists every SBC filing under that number.
Ask anything about SBC
The research agent reads SBC's filings, financials, insider trades and 13F holders, then answers with sources.